Source-grounded facts extracted from NewAmsterdam Pharma Co N.V.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NewAmsterdam Pharma Co N.V. shareholders approved Non-binding advisory vote on 2025 compensation of named executive officers at the 2026-06-02 meeting.
“Proposal 9. The Company’s shareholders approved the 2025 compensation of the Company’s named executive officers by a non-binding, advisory (“Say-on-Pay”) vote. The votes cast were as follows: For Against Abstain Broker Non-Votes 81,100,259 4,946,963 339,780 5,151,610”
NewAmsterdam Pharma Co N.V. shareholders approved Approval of ESPP at the 2026-06-02 meeting.
“Proposal 8. The Company’s shareholders approved the ESPP. The votes cast were as follows: For Against Abstain Broker Non-Votes 86,221,442 139,927 25,633 5,151,610”
NewAmsterdam Pharma Co N.V. shareholders approved Extension of authorization for Board to limit or exclude pre-emption rights for five-year period ending June 2, 2031 at the 2026-06-02 meeting.
“Proposal 7. The Company’s shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031. The votes cast were as follows: For Against Abstain Broker Non-Votes 57,890,766 28,450,917 45,319 5,151,610”
NewAmsterdam Pharma Co N.V. shareholders approved Extension of authorization for Board to issue Ordinary Shares for five-year period ending June 2, 2031 at the 2026-06-02 meeting.
“Proposal 6. The Company’s shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company’s capital, for a five-year period ending June 2, 2031. The votes cast were as follows: For Against Abstain Broker Non-Votes 59,539,558 26,801,646 45,798 5,151,610”
NewAmsterdam Pharma Co N.V. shareholders approved Re-appointment of two non-executive directors at the 2026-06-02 meeting.
“Proposal 5. The Company’s shareholders approved the re-appointment of each of the two nominees listed below as a non-executive director of the Company, each to serve until the annual general meeting of shareholders in 2030, or until their earlier death, resignation or removal. The votes cast were as follows: Name For Against Abstain Broker Non-Votes John W. Smither 85,375,639 956,620 54,743 5,151,610 Janneke van der Kamp 75,256,863 9,899,189 1,230,950 5,151,610”
NewAmsterdam Pharma Co N.V. shareholders approved Ratification of Deloitte Accountants B.V. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
“Proposal 4. The Company’s shareholders ratified the selection by the Company’s Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,502,639 4,618 31,355 —”
NewAmsterdam Pharma Co N.V. shareholders approved Instruction to Deloitte Accounts B.V. as external auditor for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
“Proposal 3. The Company’s shareholders approved the instruction to Deloitte Accounts B.V. as the external auditor of the Company’s Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,502,529 4,636 31,447 —”
NewAmsterdam Pharma Co N.V. shareholders approved Discharge from liability for the Company’s directors for fiscal year ended December 31, 2025 at the 2026-06-02 meeting.
“Proposal 2. The Company’s shareholders approved the discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2025. The votes cast were as follows: For Against Abstain Broker Non-Votes 85,229,605 1,105,840 51,557 5,151,610”
NewAmsterdam Pharma Co N.V. shareholders approved Adoption of Dutch statutory annual accounts for fiscal year ended December 31, 2025 at the 2026-06-02 meeting.
“Proposal 1. The Company’s shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,484,326 3,855 50,431 —”
NewAmsterdam Pharma Co N.V. reported financial results for the quarter ended March 31, 2026.
“On May 7, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2026.”
Adele Gulfo was appointed as Director at NewAmsterdam Pharma Co N.V..
“On April 15, 2025, the board of directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”) appointed Adele Gulfo to serve as a member of the Board.”
Mark C. McKenna was appointed as Director at NewAmsterdam Pharma Co N.V..
“On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.”
Wouter Joustra was appointed as Director at NewAmsterdam Pharma Co N.V..
“On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.”
Sander Slootweg resigned as Director at NewAmsterdam Pharma Co N.V..
“On July 16, 2024, Sander Slootweg notified NewAmsterdam Pharma Company N.V. (the “Company”) of his decision to resign as a member of the Company’s board of directors (the “Board”) effective immediately.”
NewAmsterdam Pharma Co N.V. reported financial results for quarter ended March 31, 2024.
“On May 9, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2024.”
Juliette Audet resigned as Director at NewAmsterdam Pharma Co N.V..
“In connection with Ms. Audet’s appointment as CBO, the Company’s board of directors (the “Board”) and Ms. Audet determined, as of March 28, 2024, that she will resign, effective April 1, 2024, from the Board.”
Juliette Audet was appointed as Chief Business Officer at NewAmsterdam Pharma Co N.V..
“On April 1, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) announced the appointment of Juliette Audet as Chief Business Officer (“CBO”) of the Company.”
NewAmsterdam Pharma Co N.V. reported financial results for the full year ended December 31, 2023.
“NewAmsterdam Pharma Company N.V. (the "Company") issued a press release announcing corporate updates and its financial results for the full year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.